Dermatology Times

Amlitelimab in Atopic Dermatitis (AD) Resource Center

Learn more about Amlitelimab, a fully human, non-depleting anti-OX40-ligand monoclonal antibody

OX40-Ligand (OX40L) Pathway Resource Center

Highlighting unmet needs in atopic dermatitis (AD) and understanding disease pathogenesis

OCEANA AD Clinical Development Program Brochure

This material is non-promotional and sponsored by Sanofi.
This material is for scientific and medical education purposes only, and is intended only for US healthcare professionals.

Expert Insights Roundtable:
Amlitelimab STREAM-AD Ph2b

STREAM-AD Ph2b Manuscript

OCEANA AD Clinical
Development Program
Brochure

Amlitelimab Proposed
Mechanism of Action Video

Click Here to Return to
The OX40 Ligand Pathway
Resource Center

Expert Insights Roundtable:
Amlitelimab STREAM-AD Ph2b

STREAM-AD Ph2b Manuscript

OCEANA AD Clinical
Development Program
Brochure

Amlitelimab Proposed
Mechanism of Action Video

Click Here to Return to
The OX40 Ligand Pathway
Resource Center

Sanofi is a registered trademark of Sanofi or an affiliate.

MAT-US-2410187 v2.0 - R Expiration Date: 10/22/2025